By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Selecta Biosciences, Inc. 

480 Arsenal Street
Building One
Watertown  Massachusetts  02472  U.S.A.
Phone: 617-923-1400 Fax: 617-924-3454


Company News
Selecta Obtains Exclusive License To Proprietary Gene Therapy Vector From Massachusetts Eye And Ear 5/19/2016 11:11:31 AM
Selecta Continues To Successfully Advance Pipeline Of Novel Immunotherapeutic Candidates 10/16/2015 10:43:16 AM
Selecta Appoints Earl E. Sands, MD, As Chief Medical Officer 9/8/2015 1:08:18 PM
Massachusetts' Selecta Banks Another $38 Million 9/8/2015 6:29:05 AM
Selecta’ Synthetic Vaccine Particles Instrumental In Breakthrough Research On Mucosal Vaccines 6/19/2015 9:06:27 AM
Selecta Initiates Phase 1 Clinical Program Of SEL-212, Designed As The First Non-Immunogenic Biologic Treatment For Gout 6/10/2015 9:09:56 AM
Selecta And Genethon Collaborate To Create Next Generation Gene Therapies Using Selecta’s Synthetic Vaccine Particle Platform 5/13/2015 10:08:43 AM
Sanofi (SAN.PA) Adds Celiac Disease to the Menu With $300 Million Selecta Bet 5/13/2015 5:59:40 AM
Selecta Biosciences, Inc. To Webcast Presentation At Needham & Company’s 14th Annual Healthcare Conference 4/6/2015 10:27:12 AM
Selecta Biosciences, Inc. And Skolkovo Foundation Collaboration To Develop A Synthetic Vaccine Particle In The Field Of Immuno-Oncology 12/23/2014 10:30:41 AM